Initiation of Acid Suppression Therapy Prospective Outcomes for Laryngomalacia
Status:
Recruiting
Trial end date:
2023-03-31
Target enrollment:
Participant gender:
Summary
Laryngomalacia (LM) is the most common cause of stridor in infants. Symptoms of
gastroesophageal reflux (GER) are often seen in the setting of LM; therefore, acid
suppression therapy (AST) has been empirically used in the management of this disorder. The
investigators recently performed a retrospective chart review assessing improvement of airway
and dysphagia symptoms, weight gain, and need for surgery with AST. It was found that there
was a similar improvement between LM severity groups and most patients received AST (96.6%).
It is unclear if these improvements are due to AST or natural resolution of the disease. With
heightened concerns of side effects related to AST in infants, particularly among those born
prematurely, judicious use of these medications is needed. The investigators are now
performing a prospective study looking at the outcome differences in patients with
laryngomalacia who are evaluated by speech language therapy (SLP) alone versus those with SLP
evaluation and acid suppression therapy (famotidine).